SKYE
Skye Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.53
−1.29%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -19.9%
- EBIT
- -13.7%
- EPS
- —
- Free cash flow
- +99.6%
- Operating cash flow
- +99.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +41.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -92.6%
- Net income
- —
- EPS
- -93.2%
- Free cash flow
- -60.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026